Vaishalee P Kenkre

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. doi request reprint The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways
    Vaishalee P Kenkre
    University of Wisconsin, Madison, WI 53705, USA
    Curr Hematol Malig Rep 7:216-20. 2012
  2. pmc Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network
    Vaishalee P Kenkre
    Department of Medicine, University of Wisconsin, Madison, WI, USA
    Leuk Lymphoma 52:1675-80. 2011
  3. doi request reprint Follicular lymphoma: emerging therapeutic strategies
    Vaishalee P Kenkre
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, 1111 Highland Avenue, 4059 WIMR, Madison, WI 53705, USA
    Expert Rev Hematol 3:485-95. 2010
  4. ncbi request reprint What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?
    Vaishalee P Kenkre
    Division of Hematology Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, Madison, WI 53705, USA
    Cancer J 18:383-9. 2012

Detail Information

Publications4

  1. doi request reprint The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways
    Vaishalee P Kenkre
    University of Wisconsin, Madison, WI 53705, USA
    Curr Hematol Malig Rep 7:216-20. 2012
    ..This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K...
  2. pmc Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network
    Vaishalee P Kenkre
    Department of Medicine, University of Wisconsin, Madison, WI, USA
    Leuk Lymphoma 52:1675-80. 2011
    ..No late toxicities were noted in our cohort. These long-term results suggest that the modified R-hyperCVAD regimen with maintenance rituximab is an excellent option for older patients with newly diagnosed mantle cell lymphoma...
  3. doi request reprint Follicular lymphoma: emerging therapeutic strategies
    Vaishalee P Kenkre
    Department of Medicine, Division of Hematology Oncology, University of Wisconsin School of Medicine and Public Health and the UW Carbone Cancer Center, University of Wisconsin, 1111 Highland Avenue, 4059 WIMR, Madison, WI 53705, USA
    Expert Rev Hematol 3:485-95. 2010
    ..Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification...
  4. ncbi request reprint What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma?
    Vaishalee P Kenkre
    Division of Hematology Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, and the UW Carbone Cancer Center, Madison, WI 53705, USA
    Cancer J 18:383-9. 2012
    ..The goals of this review were to provide a framework for decision making and review the literature supporting the various options...